References
- RuggeriZMPlatelets in atherothrombosisNat Med200281227123412411949
- GurbelPABlidenKPGuyerKPlatelet reactivity in patients and recurring events post-stenting. Results of the PREPARE POST-STENTING studyJ Am Coll Cardiol2005461820182616286165
- SteinhublPBBergerJTMannIIIEarly and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trialJAMA20022882411242012435254
- MehtaSRYusufSPetersRJEffects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE studyLancet200135852753311520521
- BilletNHAntiplatelet agents and arterial thrombosisCardiol Clin20082618920118406994
- HochholzerWTrenkDBestehornHPImpact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placementJ Am Coll Cardiol2006481742175017084243
- BuonamiciPMarcucciRMiglioriniAImpact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosisJ Am Coll Cardiol2007492312231717572245
- NiitsuYJakubowskiJASugidachiAAsaiFPharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activitySemin Thromb Hemost20053118419415852222
- SugidachiAAsaiFOgawaTInoueTKoikeHThe in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist propertiesBr J Pharmacol20001291439144610742300
- FaridNASmithRLGillespieTAThe disposition of prasugrel, a novel thienopyridine, in humansDrug Metab Dispos2007351096110417403916
- RehmelJLEcksteinJAFaridNAInteractions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent with the cytochromes P450Drug Metab Dispos20063460060716415119
- BrandtJTCloseSLIturriaSJCommon polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrelJ Thromb Haemost200752429243617900275
- FaridNAPayneCDSmallDSCytochrome P450 3A inhibition by ketoconazole affects prsaugrel and clopidogrel pharmacokinetics and pharmacodynamics differentlyClin Pharmacol Ther20078173574117361128
- AsaiFJakubowskiJANaganumaHPlatelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: A single-ascending dose study in healthy humansPlatelets20061720921716769598
- JakubowskiJAMatsushimaNAsaiFA multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humansBr J Clin Pharm200663421430
- MatsushimaNJakubowskiJAAsaiFPlatelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: A multiple-dose study in healthy humansPlatelets20061721822616769599
- BrandtJTPayneCDWiviottSDA comparison of prasugrel and clopidogrel loading doses on platelet function: Magnitude of platelet inhibition is related to active metabolite formationAm Heart J200715366.e9e1617174640
- JakubowskiJAPayneCDWeerakkodyGJDose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjectsJ Cardiovasc Pharmocol200749167173
- JernbergTPayneCDWintersKJPrasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery diseaseEur Heart J2006271166117316621870
- WiviottSDAntmanEMWintersKJRandomized comparison of prasugrel (CS-747,LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: Results of the Joint Utilizationì of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trialCirculation20051113366337315967851
- WiviottSDBraunwaldEMcCabeCHA clinical trial of prasugrel vs. clopidogrel in patients with acute coronary syndromesN Engl J Med20073572001201517982182
- WiviottSDTrenkDFrelingerALPRINCIPLE-TIMI 44 InvestigatorsPrasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trialCirculation20071162923293218056526